MA27001A1 - Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 - Google Patents

Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7

Info

Publication number: MA27001A1
Authority: MA; Morocco
Prior art keywords: diesterase; phospho; inhibitors; novel; spirotricyclic
Prior art date: 2001-03-21

Application number

MA27310A

Other languages

English (en)

Inventor

Edwige Lorthiois

Pierre Ducrot

Fabrice Vergne

Patrick Bernardelli

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2003-09-12

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-12 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2004-12-20 Publication of MA27001A1 publication Critical patent/MA27001A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

MA27310A 2001-03-21 2003-09-12 Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 MA27001A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2001/003355 WO2002076953A1 (fr)	2001-03-21	2001-03-21	Nouveaux derives spirotricycliques et utilisation de ces derives en tant qu'inhibiteurs de la phosphodiesterase-7

Publications (1)

Publication Number	Publication Date
MA27001A1 true MA27001A1 (fr)	2004-12-20

Family

ID=8164349

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27310A MA27001A1 (fr)	2001-03-21	2003-09-12	Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7

Country Status (47)

Country	Link
US (3)	US20020198198A1 (fr)
EP (2)	EP1801106A3 (fr)
JP (1)	JP4086663B2 (fr)
KR (1)	KR100617435B1 (fr)
CN (1)	CN100447136C (fr)
AP (1)	AP1699A (fr)
AR (1)	AR033617A1 (fr)
AT (1)	ATE367381T1 (fr)
AU (1)	AU2002304800B2 (fr)
BG (1)	BG108181A (fr)
BR (1)	BR0208192A (fr)
CA (1)	CA2441313C (fr)
CU (1)	CU23218A3 (fr)
CY (1)	CY1106829T1 (fr)
CZ (1)	CZ20032451A3 (fr)
DE (1)	DE60221233T2 (fr)
DK (1)	DK1373224T3 (fr)
EA (1)	EA006815B1 (fr)
EC (1)	ECSP034750A (fr)
EE (1)	EE200300459A (fr)
ES (1)	ES2288552T3 (fr)
GE (1)	GEP20053631B (fr)
GT (1)	GT200200053A (fr)
HK (1)	HK1061854A1 (fr)
HR (1)	HRP20030740A2 (fr)
HU (1)	HUP0303637A3 (fr)
IL (2)	IL157659A0 (fr)
IS (1)	IS2529B (fr)
MA (1)	MA27001A1 (fr)
MX (1)	MXPA03008485A (fr)
MY (1)	MY142045A (fr)
NO (1)	NO326086B1 (fr)
NZ (1)	NZ527847A (fr)
OA (1)	OA12454A (fr)
PA (1)	PA8541601A1 (fr)
PE (1)	PE20021010A1 (fr)
PL (1)	PL367058A1 (fr)
PT (1)	PT1373224E (fr)
RS (1)	RS50429B (fr)
SI (1)	SI1373224T1 (fr)
SK (1)	SK11562003A3 (fr)
SV (1)	SV2003000925A (fr)
TN (1)	TNSN03076A1 (fr)
TW (1)	TWI267509B (fr)
UA (1)	UA74243C2 (fr)
WO (2)	WO2002076953A1 (fr)
ZA (1)	ZA200306601B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1400244A1 (fr)	2002-09-17	2004-03-24	Warner-Lambert Company LLC	Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
GB0230195D0 (en) *	2002-12-24	2003-02-05	Biofocus Plc	Compound Libraries
EP2617419A1 (fr)	2003-04-24	2013-07-24	Incyte Corporation	Dérivés d'aza-spiro-alcanes utilisés comme inhibiteurs de métalloprotéases
JP2006219373A (ja)	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja)	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
CN1835753A (zh) *	2003-08-12	2006-09-20	弗·哈夫曼-拉罗切有限公司	作为促皮质释放素(cfr)拮抗剂的螺－取代的四氢喹唑啉
EP2433943B1 (fr)	2004-07-01	2013-09-11	Daiichi Sankyo Company, Limited	Intermédiaires pour dérivés de thiénopyrazole ayant une activité inhibitrice de la PDE7
GB0504209D0 (en) *	2005-03-01	2005-04-06	Pfizer Ltd	New use of PDE7 inhibitors
WO2006092692A1 (fr) *	2005-03-01	2006-09-08	Pfizer Limited	Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
WO2006092691A1 (fr) *	2005-03-01	2006-09-08	Pfizer Limited	Utilisation des inhibiteurs de pde7 pour le traitement de la douleur neuropathique
KR100680497B1 (ko) *	2005-07-25	2007-02-08	엘지전자 주식회사	근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
EP1928437A2 (fr)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenese par modulation du recepteur muscarinique
EP2258357A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse avec inhibiteur de l'acetylcholinestérase
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr)	2005-10-31	2007-05-10	Braincells, Inc.	Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US8067433B2 (en)	2005-11-09	2011-11-29	Zalicus Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
JP2009517453A (ja)	2005-12-02	2009-04-30	ファイザー・リミテッド	Ｐｄｅ７阻害剤としてのスピロ環式キナゾリン誘導体
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
EP2377531A2 (fr)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogénèse par modulation de l'angiotensine
MX2009002496A (es) *	2006-09-08	2009-07-10	Braincells Inc	Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
CN101917992A (zh) *	2007-03-27	2010-12-15	奥默罗斯公司	用于治疗运动障碍的pde7抑制剂的用途
US8637528B2 (en)	2007-03-27	2014-01-28	Omeros Corporation	Use of PDE7 inhibitors for the treatment of movement disorders
CA2687944A1 (fr) *	2007-05-24	2008-11-27	Pfizer Limited	Derives spirocycliques
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
CN107375296A (zh)	2010-11-08	2017-11-24	奥默罗斯公司	使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2012088266A2 (fr)	2010-12-22	2012-06-28	Incyte Corporation	Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
US20150119399A1 (en)	2012-01-10	2015-04-30	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
NZ702747A (en)	2012-06-13	2017-03-31	Incyte Holdings Corp	Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (fr)	2012-08-10	2014-02-13	Incyte Corporation	Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
EP2986610B9 (fr)	2013-04-19	2018-10-17	Incyte Holdings Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr)	2015-02-20	2016-08-25	Incyte Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9708318B2 (en)	2015-02-20	2017-07-18	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CA3008689A1 (fr) *	2015-12-16	2017-06-22	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Analogue de pyrido[1,2-a]pyrimidone, sa forme cristalline, son intermediaire et son procede de preparation
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) *	2017-07-04	2017-11-24	孙秀芹	一种治疗盆腔炎的化合物及制备方法和应用
MX2020000295A (es) *	2017-07-12	2020-07-22	Dart Neuroscience Llc	Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
CR20200591A (es)	2018-05-04	2021-03-31	Incyte Corp	Sales de un inhibidor de fgfr
IL312465A (en)	2018-05-04	2024-06-01	Incyte Corp	FGFR inhibitor solid forms and processes for their preparation
WO2020185532A1 (fr)	2019-03-08	2020-09-17	Incyte Corporation	Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TW202128685A (zh)	2019-10-14	2021-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4069696A1 (fr)	2019-12-04	2022-10-12	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US11407750B2 (en)	2019-12-04	2022-08-09	Incyte Corporation	Derivatives of an FGFR inhibitor
WO2021146424A1 (fr)	2020-01-15	2021-07-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環
WO2024038089A1 (fr)	2022-08-18	2024-02-22	Mitodicure Gmbh	Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5815979A (ja)	1981-07-11	1983-01-29	Kyowa Hakko Kogyo Co Ltd	新規なピペリジン誘導体およびその製造法
US4764512A (en)	1986-08-27	1988-08-16	Rorer Pharmaceutical Corporation	Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) *	1988-11-22	1993-01-25	Tanabe Seiyaku Co	Μεθοδος παραγωγης παραγωγων κιναζολινονης.
HUT72076A (en)	1992-12-11	1996-03-28	Merck & Co Inc	Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5578593A (en)	1992-12-11	1996-11-26	Merck & Co., Inc.	Spiro piperidines and homologs promote release of growth hormone
US5602143A (en) *	1994-12-08	1997-02-11	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
KR19990064276A (ko) *	1995-10-17	1999-07-26	니콜라스 피터 비가르트 (니크 비가르트), 콜린 레드롭	제약학적으로 활성인 퀴나졸린 화합물
CN1205008A (zh) *	1996-08-30	1999-01-13	协和发酵工业株式会社	咪唑并喹唑啉衍生物
US6509334B1 (en)	1999-05-04	2003-01-21	American Home Products Corporation	Cyclocarbamate derivatives as progesterone receptor modulators
WO2000066164A1 (fr)	1999-05-04	2000-11-09	American Home Products Corporation	Compositions contraceptives contenant des agents antiprogestatifs et progestatifs
WO2000066560A1 (fr) *	1999-05-04	2000-11-09	American Home Products Corporation	Derives de quinazolinone et de benzoxazine tenant lieu de modulateurs du recepteur de progesterone
US6498154B1 (en)	1999-05-04	2002-12-24	Wyeth	Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en)	1999-05-04	2002-03-19	American Home Products Corporation	Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2001045707A1 (fr)	1999-12-21	2001-06-28	Merck & Co., Inc.	Inhibiteurs de prenyl-proteine transferase
UA73119C2 (en)	2000-04-19	2005-06-15	American Home Products Corpoir	Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

2001
- 2001-03-21 AP APAP/P/2003/002857A patent/AP1699A/en active
- 2001-03-21 WO PCT/EP2001/003355 patent/WO2002076953A1/fr active Application Filing
2002
- 2002-03-05 TW TW091104028A patent/TWI267509B/zh not_active IP Right Cessation
- 2002-03-18 PT PT02732544T patent/PT1373224E/pt unknown
- 2002-03-18 KR KR1020037012247A patent/KR100617435B1/ko not_active IP Right Cessation
- 2002-03-18 TN TNPCT/EP2002/003594A patent/TNSN03076A1/fr unknown
- 2002-03-18 JP JP2002573763A patent/JP4086663B2/ja not_active Expired - Fee Related
- 2002-03-18 NZ NZ527847A patent/NZ527847A/en unknown
- 2002-03-18 UA UA2003098601A patent/UA74243C2/uk unknown
- 2002-03-18 EE EEP200300459A patent/EE200300459A/xx unknown
- 2002-03-18 SI SI200230587T patent/SI1373224T1/sl unknown
- 2002-03-18 IL IL15765902A patent/IL157659A0/xx active IP Right Grant
- 2002-03-18 DE DE60221233T patent/DE60221233T2/de not_active Expired - Lifetime
- 2002-03-18 CA CA002441313A patent/CA2441313C/fr not_active Expired - Fee Related
- 2002-03-18 AT AT02732544T patent/ATE367381T1/de not_active IP Right Cessation
- 2002-03-18 RS YUP-740/03A patent/RS50429B/sr unknown
- 2002-03-18 AU AU2002304800A patent/AU2002304800B2/en not_active Ceased
- 2002-03-18 ES ES02732544T patent/ES2288552T3/es not_active Expired - Lifetime
- 2002-03-18 CN CNB028069714A patent/CN100447136C/zh not_active Expired - Fee Related
- 2002-03-18 BR BR0208192-0A patent/BR0208192A/pt not_active IP Right Cessation
- 2002-03-18 DK DK02732544T patent/DK1373224T3/da active
- 2002-03-18 HU HU0303637A patent/HUP0303637A3/hu unknown
- 2002-03-18 GE GE5294A patent/GEP20053631B/en unknown
- 2002-03-18 EP EP07104642A patent/EP1801106A3/fr not_active Withdrawn
- 2002-03-18 EA EA200300906A patent/EA006815B1/ru unknown
- 2002-03-18 PL PL02367058A patent/PL367058A1/xx not_active Application Discontinuation
- 2002-03-18 OA OA1200300226A patent/OA12454A/en unknown
- 2002-03-18 MX MXPA03008485A patent/MXPA03008485A/es active IP Right Grant
- 2002-03-18 WO PCT/EP2002/003594 patent/WO2002074754A1/fr active Application Filing
- 2002-03-18 CZ CZ20032451A patent/CZ20032451A3/cs unknown
- 2002-03-18 EP EP02732544A patent/EP1373224B1/fr not_active Expired - Lifetime
- 2002-03-18 MY MYPI20020954A patent/MY142045A/en unknown
- 2002-03-18 SK SK1156-2003A patent/SK11562003A3/sk not_active Application Discontinuation
- 2002-03-19 US US10/101,996 patent/US20020198198A1/en not_active Abandoned
- 2002-03-20 SV SV2002000925A patent/SV2003000925A/es not_active Application Discontinuation
- 2002-03-20 PE PE2002000212A patent/PE20021010A1/es not_active Application Discontinuation
- 2002-03-20 GT GT200200053A patent/GT200200053A/es unknown
- 2002-03-20 PA PA20028541601A patent/PA8541601A1/es unknown
- 2002-03-20 AR ARP020100993A patent/AR033617A1/es active IP Right Grant
2003
- 2003-08-25 ZA ZA200306601A patent/ZA200306601B/en unknown
- 2003-08-27 EC EC2003004750A patent/ECSP034750A/es unknown
- 2003-08-28 IL IL157659A patent/IL157659A/en not_active IP Right Cessation
- 2003-08-29 IS IS6934A patent/IS2529B/is unknown
- 2003-08-29 CU CU20030188A patent/CU23218A3/es not_active IP Right Cessation
- 2003-09-12 MA MA27310A patent/MA27001A1/fr unknown
- 2003-09-15 HR HR20030740A patent/HRP20030740A2/hr not_active Application Discontinuation
- 2003-09-17 BG BG108181A patent/BG108181A/xx active Pending
- 2003-09-19 NO NO20034187A patent/NO326086B1/no not_active IP Right Cessation
2004
- 2004-05-24 US US10/852,404 patent/US7214676B2/en not_active Expired - Fee Related
- 2004-07-06 HK HK04104855.2A patent/HK1061854A1/xx not_active IP Right Cessation
2006
- 2006-10-20 US US11/551,687 patent/US20070049558A1/en not_active Abandoned
2007
- 2007-08-30 CY CY20071101121T patent/CY1106829T1/el unknown

Also Published As

Publication number	Publication date
IS2529B (is)	2009-07-15
HUP0303637A3 (en)	2004-07-28
AP1699A (en)	2006-12-26
US20070049558A1 (en)	2007-03-01
NO20034187L (no)	2003-10-15
HUP0303637A2 (hu)	2004-03-01
CN100447136C (zh)	2008-12-31
OA12454A (en)	2004-09-30
DK1373224T3 (da)	2007-10-15
CU23218A3 (es)	2007-07-20
RS50429B (sr)	2009-12-31
PE20021010A1 (es)	2003-02-01
PL367058A1 (en)	2005-02-21
CZ20032451A3 (cs)	2004-09-15
CY1106829T1 (el)	2012-05-23
TNSN03076A1 (fr)	2005-12-23
NO326086B1 (no)	2008-09-15
GT200200053A (es)	2003-02-12
HK1061854A1 (en)	2004-10-08
SK11562003A3 (sk)	2005-01-03
EA006815B1 (ru)	2006-04-28
JP4086663B2 (ja)	2008-05-14
MY142045A (en)	2010-08-30
KR20030086315A (ko)	2003-11-07
US20020198198A1 (en)	2002-12-26
AU2002304800B2 (en)	2007-08-30
ZA200306601B (en)	2004-08-25
EA200300906A1 (ru)	2004-02-26
CA2441313A1 (fr)	2002-09-26
CN1498212A (zh)	2004-05-19
CA2441313C (fr)	2009-03-31
YU74003A (sh)	2006-05-25
WO2002074754A1 (fr)	2002-09-26
ES2288552T3 (es)	2008-01-16
UA74243C2 (uk)	2005-11-15
EP1373224B1 (fr)	2007-07-18
US20040214843A1 (en)	2004-10-28
ATE367381T1 (de)	2007-08-15
BG108181A (en)	2004-09-30
NO20034187D0 (no)	2003-09-19
DE60221233T2 (de)	2008-04-03
JP2004529123A (ja)	2004-09-24
HRP20030740A2 (en)	2005-06-30
IS6934A (is)	2003-08-29
TWI267509B (en)	2006-12-01
SV2003000925A (es)	2003-05-20
MXPA03008485A (es)	2003-12-08
US7214676B2 (en)	2007-05-08
EP1801106A3 (fr)	2007-07-04
PA8541601A1 (es)	2003-05-14
IL157659A (en)	2008-08-07
DE60221233D1 (de)	2007-08-30
EP1801106A2 (fr)	2007-06-27
AP2003002857A0 (en)	2003-09-30
EP1373224A1 (fr)	2004-01-02
WO2002076953A1 (fr)	2002-10-03
SI1373224T1 (sl)	2007-10-31
KR100617435B1 (ko)	2006-08-31
AR033617A1 (es)	2003-12-26
PT1373224E (pt)	2007-09-25
BR0208192A (pt)	2004-03-02
GEP20053631B (en)	2005-10-10
IL157659A0 (en)	2004-03-28
EE200300459A (et)	2004-02-16
ECSP034750A (es)	2003-10-28
NZ527847A (en)	2005-06-24

Publication	Publication Date	Title
MA27001A1 (fr)	2004-12-20	Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7
FR13C0061I2 (fr)	2014-11-07	Composes 4-oxoquinolines et leur utilisation comme inhibiteurs du hiv-integrase
FR12C0019I2 (fr)	2013-08-16	O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
CY2013005I2 (el)	2015-11-04	Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
AR028576A1 (es)	2003-05-14	Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
ATE269327T1 (de)	2004-07-15	Imidazol-5-yl-2-anilino-pyrimidine als inhibitoren der zellproliferation
MA27230A1 (fr)	2005-02-01	Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
NO20041293L (no)	2004-05-27	Alkyn-aryl-fosfodiesterase-4-inhibitorer
IS6656A (is)	2002-12-17	Útskiptar kínasólínafleiður og notkun þeirra sem hemla
AR028575A1 (es)	2003-05-14	Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
CY2012026I2 (el)	2015-08-05	Παραγωγα κουιναζολινης ως αναστολεις vegf
ATE269701T1 (de)	2004-07-15	Gyrase-inhibitoren und ihre verwendung
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
DE60208661D1 (de)	2006-04-06	Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
MXPA03001848A (es)	2003-06-04	Derivados de fenoxibencilamina como inhibidores de la reabsorcion de serotonina.
DZ3357A1 (fr)	2001-11-22	Nouveaux médicaments composés de dibenzoazulène comme inhibiteurs de facteur onconécrosant
DE60200374D1 (de)	2004-05-19	Endoparasitizide Gelzusammensetzung
DZ3367A1 (fr)	2001-12-13	Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase
DE60031450D1 (de)	2006-11-30	Polymorph v von torasemid
EE200200389A (et)	2003-10-15	Imidasooli uued derivaadid
IS6468A (is)	2002-07-11	Heterósýklískar amíð afleiður
AR028075A1 (es)	2003-04-23	Inhibidores de la peptido-desformilasa
DE60331820D1 (de)	2010-05-06	Beseitigung von verstopfungen von rohrleitungen
FR2819255B1 (fr)	2003-02-28	Derives chimiques et leur application comme agent antitelomerase
DZ3366A1 (fr)	2001-12-13	Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase